# US 2024/0190986 A1 · Mesothelin binding molecule and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0190986 A1
- Document ID: US20240190986A1
- Status: Published application
- Kind: A1
- Application number: 18/269,945
- Filed: 2021-12-27
- Published: 2024-06-13
- Earliest claimed: 2020-12-28
- Assignees: Zhejiang Nanomab Technology Center Co. Ltd.
- Applicants: Zhejiang Nanomab Technology Center Co. Ltd.
- Inventors: Jiaguo LI; Haixiang YU; Xiangzhen LIU; Weimin ZHU; Yan SUN; Na DING; Qijun QIAN
- Web page: https://patentgrep.com/patent/US20240190986A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 16/30: from tumour cells
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12N 2710/00: dsDNA viruses
- C12N 2795/14131: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a mesothelin binding molecule, comprising an anti-mesothelin single domain antibody. Complementarity determining regions (CDR) of the single domain antibody comprise CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3.

## Claims

### Claim 1

A mesothelin binding molecule, comprising an anti-mesothelin single domain antibody, wherein the complementarity determining region (CDR) of the single domain antibody comprises CDR1, CDR2 and CDR3, and CDR1 comprises the sequence shown in SEQ ID NO: 1, CDR2 comprises the sequence shown in SEQ ID NO: 2, and CDR3 comprises the sequence shown in SEQ ID NO: 3, wherein,
SEQ ID NO: 1 is X1X2X3X4X5X6X7X8X9X10X11, wherein X1 is G, E, T or A, X2 is S, N, P, A, H, D, K, I or F, X3 is I, S, V, T, D, L, A, M or H, X4 is F, S, I, A, L or G, X5 is N, S, G, A, D, T, E, R or H, X6 is I, L, F, Y, E or N, X7 is N, A, G, D, K, Y, L or S, X8 is A, Y, V, D or N, X9 is E or null, X10 is F or null, X11 is A or null,
SEQ ID NO: 2 is X1X2X3X4X5X6X7X8X9X10X11X12, wherein X1 is I, M, A, T or L, X2 is S, G, N, D, T or V, X3 is S, N, A, R, G or T, X4 is S, T, G, D or N, X5 is N, G, T or I, X6 is S, R, N, D, K, T or G, X7 is D, T, S, I or K, X8 is N, T, G, D or null, X9 is T, K, G or null, X10 is G, R or null, X11 is V, T or null, X12 is T or null,
SEQ ID NO: 3 is X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23, wherein X1 is N, H, A or Q, X2 is L, A, G or V, X3 is S, R, E, G, D or T, X4 is N, A, R, G, D, K, V, T, I, E or Q, X5 is Y, F, K, S, C, I, D, G, H or R, X6 is D, A, V, G, R, N, P, T, C, Q or S, X7 is R, Y, T, A, D, K, L, E, S or G, X8 is K, S, F, T, D, Q, E, G, P, R, Y or N, X9 is D, G, I, H, S, Y, Q, K, T, R or V, X10 is R, Y, H, N, T, D, P, V, K, C, L or S, X11 is Y, D, E, P, F, S, L, I or null, X12 is P, V, Q, A, Y, F, N, D, R or null, X13 is D, A, Y, V, Q, P or null, X14 is Y, L, P, A, E or null, X15 is C, S, M, P, T or null, X15 is C, S, M, P or null, X16 is V, D, S, Y or null, X17 is L, F, V, D or null, X18 is R, G, M, S or null, X19 is D, N, S or null, X20 is Y, L or null, X21 is Y or null, X22 is A or null, X23 is D or null.

### Claim 2 (depends on 1)

The mesothelin binding molecule according to claim 1, wherein,
SEQ ID NO:1 is X1X2X3X4X5X6X7X8, wherein X1 is G, E, T or A, X2 is S, N, P, A, H, D, K, I or F, X3 is I, S, V, T, D, L, A, M or H, X4 is F, S, I, A, L or G, X5 is N, S, G, A, D, T, E or H, X6 is I, L, F, Y or N, X7 is N, A, G, D, K, Y or S, X8 is A, Y, V or N,
SEQ ID NO: 2 is X1X2X3X4X5X6X7X8X9X10X11X12, wherein X1 is I, M, A, T or L, X2 is S, G, N, D, T or V, X3 is S, N, A, R or T, X4 is S, T, G, D or N, X5 is N, G, T or I, X6 is S, R, N, D, K, T or G, X7 is D, T, S, I or K, X8 is N, T, G, D or null, X9 is T, K, G or null, X10 is G, R or null, X11 is V, T or null, X12 is T or null,
SEQ ID NO: 3 is X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23, wherein X1 is N, H, A or Q, X2 is L, A, G or V, X3 is S, R, E, G, D or T, X4 is N, A, R, G, D, K, V, T, I or Q, X5 is Y, F, K, S, C, I, D, G, H or R, X6 is D, A, V, G, R, N, P, T, C, Q or S, X7 is R, Y, T, A, D, K, L, E, S or G, X8 is K, S, F, T, D, Q, E, G, P, R, Y or N, X9 is D, G, I, H, S, Y, Q, K, Tor V, X10 is R, Y, H, N, T, D, P, V, K, C or S, X11 is Y, D, E, P, F, S, L or null, X12 is P, V, Q, A, Y, F, N, D or null, X13 is D, A, Y, V, Q or null, X14 is Y, L, P, A, E or null, X15 is C, S, M, P or null, X16 is V, D, S, Y or null, X17 is L, F, V, D or null, X18 is R, G, M, S or null, X19 is D, N, S or null, X20 is Y, L or null, X21 is Y or null, X22 is A or null, X23 is D or null.

### Claim 3 (depends on 1)

The mesothelin binding molecule according to claim 1, wherein CDR1 of the single domain antibody comprises the sequence shown in any one of SEQ ID NOS: 4-27 and 73, CDR2 of the single domain antibody comprises the sequence shown in any one of SEQ ID NOs: 28-47 and 74, and CDR3 of the single domain antibody comprises the sequence shown in any one of SEQ ID NOs: 48-72 and 75.

### Claim 4 (depends on 1)

The mesothelin binding molecule according to claim 1, wherein,
the FR region of the single domain antibody comprises the FR region of any VHH selected from SEQ ID NOs: 76-120.

### Claim 5 (depends on 4)

The mesothelin binding molecule according to claim 4, wherein the mesothelin binding molecule is a heavy chain antibody, which further comprises heavy chain constant regions CH2 and CH3.

### Claim 6 (depends on 1)

A polynucleotide, wherein the polynucleotide comprises a sequence selected from:
(1) a coding sequence of the mesothelin binding molecule according to claim 1;
(2) a complementary sequence of (1);
(3) a 5-50 bp fragment of any sequence of (1) or (2).

### Claim 7 (depends on 6)

A nucleic acid construct, wherein the nucleic acid construct comprises the polynucleotide of claim 6.

### Claim 8 (depends on 1)

A phage comprising the mesothelin binding molecule according to claim 1.

### Claim 9 (depends on 1)

A host cell, wherein the host cell:
(1) expresses the mesothelin binding molecule according to claim 1; and/or
(2) comprises a polynucleotide comprising a coding sequence of the mesothelin binding molecule or a complementary sequence of the coding sequence; and/or
(3) comprises a nucleic acid construct comprising the polynucleotide of (2).

### Claim 10 (depends on 9)

A method for producing mesothelin binding molecule, comprising: culturing the host cell according to claim 9 under conditions suitable for producing the mesothelin binding molecule, and optionally purifying the mesothelin binding molecule from the culture.

### Claim 11 (depends on 1)

A pharmaceutical composition, comprising the mesothelin binding molecule according to claim 1, a polynucleotide comprising a coding sequence of the mesothelin binding molecule or a complementary sequence of the coding sequence, a nucleic acid construct comprising the polynucleotide, or a phage comprising the mesothelin binding molecule, and a pharmaceutically acceptable excipient.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A kit for detecting mesothelin or MD50, which is used to evaluate the therapeutic effect of a medicament or diagnose cancer, wherein the kit comprises the mesothelin binding molecule according to claim 1, a polynucleotide comprising a coding sequence of the mesothelin binding molecule or a complementary sequence of the coding sequence, a nucleic acid construct comprising the polynucleotide, or a phage comprising the mesothelin binding molecule.

### Claim 14 (depends on 1)

A method for detecting the presence of mesothelin or MD50 in a sample, wherein the method comprises: incubating the mesothelin binding molecule according to claim 1 with the sample, and detecting the binding of mesothelin or MD50 to a single domain antibody, antibody, or antigen binding fragment thereof, thereby determining the presence of mesothelin or MD50 in the sample.

### Claim 15

(canceled)

### Claim 16 (depends on 2)

The mesothelin binding molecule according to claim 2, wherein,
SEQ ID NO: 1 is X1X2X3X4X5X6X7X8, wherein X1 is G, E, T or A, X2 is S, N, P, H or I, X3 is I, S, T, D, L or A, X4 is F, I or L, X5 is S, T or E, X6 is I, For Y, X7 is N, A, D or Y, X8 is A or Y,
SEQ ID NO:2 is X1X2X3X4X5X6X7X8X9X10X11X12, wherein X1 is I, A or T, X2 is S, G, N or T, X3 is S or R, X4 is T, G or D, X5 is N, G or T, X6 is S, R, N, K or T, X7 is D, T, S, I or K, X8 is N, G or null, X9 is T, G or null, X10 is G or null, X11 is V or null, X12 is T or null,
SEQ ID NO: 3 is AX2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19, wherein X2 is A or V, X3 is S, E, G or D, X4 is N, R, D or I, X5 is Y, F, K, D or H, X6 is D, G, P, C or S, X7 is R, Y, D, K or L, X8 is K, Q, G or N, X9 is D, S, Y or Q, X10 is R, Y, D, V or S, X11 is Y, D, F, S, L or null, X12 is P, F, or null, X13 is D, V or null, X14 is P or null, X15 is S or null, X16 is D or null, X17 is F or null, X18 is G or null, X19 is N or null.

### Claim 17 (depends on 3)

The mesothelin binding molecule according to claim 3, wherein the single domain antibody comprises CDR1, CDR2, and CDR3 shown in any one of the following groups a1 to a26:
Group
CDR1
CDR2
CDR3
a1
SEQ ID
SEQ ID
SEQ ID
NO: 4
NO: 28
NO: 48
a2
SEQ ID
SEQ ID
SEQ ID
NO: 5
NO: 29
NO: 49
a3
SEQ ID
SEQ ID
SEQ ID
NO: 6
NO: 30
NO: 50
a4
SEQ ID
SEQ ID
SEQ ID
NO: 7
NO: 31
NO: 51
a5
SEQ ID
SEQ ID
SEQ ID
NO: 8
NO: 32
NO: 52
a6
SEQ ID
SEQ ID
SEQ ID
NO: 9
NO: 33
NO: 53
a7
SEQ ID
SEQ ID
SEQ ID
NO: 10
NO: 34
NO: 54
a8
SEQ ID
SEQ ID
SEQ ID
NO: 11
NO: 35
NO: 55
a9
SEQ ID
SEQ ID
SEQ ID
NO: 12
NO: 36
NO: 56
a10
SEQ ID
SEQ ID
SEQ ID
NO: 13
NO: 32
NO: 57
a11
SEQ ID
SEQ ID
SEQ ID
NO: 14
NO: 37
NO: 58
a12
SEQ ID
SEQ ID
SEQ ID
NO: 15
NO: 38
NO: 59
a13
SEQ ID
SEQ ID
SEQ ID
NO: 16
NO: 31
NO: 60
a14
SEQ ID
SEQ ID
SEQ ID
NO: 17
NO: 39
NO: 61
a15
SEQ ID
SEQ ID
SEQ ID
NO: 18
NO: 40
NO: 62
a16
SEQ ID
SEQ ID
SEQ ID
NO: 19
NO: 41
NO: 63
a17
SEQ ID
SEQ ID
SEQ ID
NO: 20
NO: 42
NO: 64
a18
SEQ ID
SEQ ID
SEQ ID
NO: 21
NO: 43
NO: 65
a19
SEQ ID
SEQ ID
SEQ ID
NO: 22
NO: 32
NO: 66
a20
SEQ ID
SEQ ID
SEQ ID
NO: 13
NO: 32
NO: 67
a21
SEQ ID
SEQ ID
SEQ ID
NO: 23
NO: 44
NO: 68
a22
SEQ ID
SEQ ID
SEQ ID
NO: 24
NO: 45
NO: 69
a23
SEQ ID
SEQ ID
SEQ ID
NO: 25
NO: 46
NO: 70
a24
SEQ ID
SEQ ID
SEQ ID
NO: 26
NO: 47
NO: 71
a25
SEQ ID
SEQ ID
SEQ ID
NO: 27
NO: 40
NO: 72
a26
SEQ ID
SEQ ID
SEQ ID
NO: 73
NO: 74
NO: 75

### Claim 18 (depends on 1)

The mesothelin binding molecule according to claim 1, wherein, the single domain antibody VHH is as shown in any one of SEQ ID NOs: 76-120.

### Claim 19 (depends on 1)

The mesothelin binding molecule according to claim 1, wherein, the mesothelin binding molecule is a monovalent or multivalent single domain antibody, a multispecific single domain antibody, a heavy chain antibody or an antigen binding fragment thereof, an antibody or an antigen binding fragment thereof comprising one, two or more of the single domain antibodies.

### Claim 20 (depends on 9)

A pharmaceutical composition, comprising the host cell according to claim 9, and a pharmaceutically acceptable excipient.

### Claim 21 (depends on 9)

A kit for detecting mesothelin or MD50, which is used to evaluate the therapeutic effect of a medicament or diagnose cancer, wherein the kit comprises the host cell according to claim 9.

### Claim 22 (depends on 1)

A method for treating or preventing cancer, comprising administrating a patient in need thereof an effective amount of a mesothelin binding molecule according to claim 1, or a pharmaceutical composition comprising the mesothelin binding molecule and a pharmaceutically acceptable excipient.
